New Technologies

SIG Leaders

Brinda Mahadevan and Patricia A. Escobar

Including the Genomic SIG since EMS 2006!

SIG Description

The mission of the New Technologies Special Interest Group is to provide a forum for discussion on existing and emerging technologies that relate to current topics in the field of mutagenesis, genetic toxicology, molecular epidemiology and toxicology. Relevant activities of this SIG may include, but are not limited to, organizing and/or sponsoring symposia, roundtable discussions, workshops; Inviting speakers to introduce new technologies, and discuss their strengths and limitations. In addition, this SIG will provide a platform for academia, industry and government agencies for discussion and guidance in incorporating new technologies into the risk assessment and safety evaluation process. Topics chosen for the proposed activities of the SIG will focus on those areas of new emerging science and technology that are deemed most likely to be of broad enough interest so as to be relevant to existing Society members while, by virtue of novel content, attracting new members; in this way, expanding the scope of the Society.

Current Year Initiatives

Coming soon.

Newsletters

2008

2007

2006

Workshop Summary (2008)

New Technologies

Nanotechnology

• National Nanotechnology Initiative
• NTP Nanotechnology Safety Initiative
• Nanotechnology at NIH
• Nanotechnology at NIBIB (National Institute of Biomedical Imaging and Bioengineering)
• Nature Nanotechnology
• PubMed search (manually enter “nanotechnology genotoxicity”)



'Omics

• Toxicogenomics Research Consortium
• National Library of Medicine, Environmental Health and Toxicology, Enviro-Health Links - Toxicogenomics
• OECD Activities to Explore and Evaluate Regulatory Application of Toxicogenomics and Molecular Screening Assays
• Metabolomics Science (The Scripps Institute for Mass Spectrometry)
• NIH Proteomics Interest Group
  

  Environmental Health Perspectives Selected Commentaries and Articles

  • Toxicogenomics: An EHP Section (2003)
  • The Reality of Pharmacogenomics: Optimizing Therapeutic Decision Making (2003)
  • Toxicogenomic Applications to Drug Risk Assessment (2003)
  • Toxicogenomics in Risk Assessment: An Overview of an HESI Collaborative Research Program (2004)
  • Toxicogenomics in Risk Assessment: Communicating the Challenges (2004)
  • Systems Biology, the Second Time Around (2004)
  • Current and Future Applications of Toxicogenomics: Results Summary of a Survey from the HESI Genomics State of Science Subcommittee (2010 Ahead of print)
  • Metabolomics—A New Exciting Field within the “omics” Sciences (2004)
  • Metabolomics: what's happening downstream of DNA (2004)
    
    

PIG-A Technology

Mutation Assay Reference Articles

• Chen, R, Eshleman, J, Brodsky R, and Medof, ME. Glycophosphatidylinositol-anchored Protein Deficiency as a Marker of Mutator Phenotypes in Cancer. Cancer Research 61, pp 654-658, January 2001.
  
  
• Brodsky, R, Hu. R. PIG-A Mutations in Paroxysmal Nocturnal Hemoglobinuria and in Normal Hematopoiesis. Leukemia and Lymphoma 47, Issue 7 pp 1215-1221. July 2006.
  
  
• Miura, D, Dobrovolsky, V, Kasahara, Y, Katsuura, Y, Heflich, R. Development of an In Vivo Gene Mutation Assay Using the Endogenous Pig-A Gene: I. Flow Cytometric Detection of CD59-negative Peripheral Red Blood Cells and CD48-Negative Spleen T-Cells from the Rat. Environmental and Molecular Mutagenesis 49, pp 614-621. July 2008.
  
  
• Miura, D, Dobrovolsky, V, Mittelstaedt, R., Kasahara, Y., Katsuura, Y., Heflich, R. Development of an In Vivo Gene Mutation Assay Using the Endogenous Pig-A Gene: II. Selection of Pig-A Mutant Rat Spleen T-Cells with Proaerolysin and Sequencing Pig-A cDNA from the Mutants. Environmental and Molecular Mutagenesis 49, pp 622-630. July 2008.
  
  
• Phonethepswath, S., Bryce, S., Bemis, J., Dertinger, S. Erythrocyte-based Pig-A Gene Mutation Assay: Demonstration of cross-species potential. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 657, 2 pp 122-126. December 2008